Immunoglobulin G for patients with necrotising soft tissue infection (INSTINCT): A randomised, blinded, placebo-controlled trial.
The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
Purpose The aim of the INSTINCT trial was to assess the effect of intravenous polyspecific immunoglobulin G (IVIG) compared with placebo on self-reported physical function in intensive care unit (ICU) patients with necrotising soft tissue infection (NSTI). Methods We randomised 100 patients with NSTI 1:1 to masked infusion of 25 g of IVIG (Privigen, CSL Behring) or an equal volume of 0.9% saline once daily for the first 3 days of ICU admission. The primary outcome was the physical component summary (PCS) score of the 36-item short form health survey (SF-36) 6 months after randomisation; patients who had died were given the lowest possible score (zero). Results Of the 100 patients randomised, 87 were included in the intention-to-treat analysis of the PCS score, 42 patients (84%) in the IVIG group and 45 patients (90%) in the placebo group. The two intervention groups had similar baseline characteristics with the exception of IVIG use before randomisation (1 dose was allowed) and rates of acute kidney injury. Median PCS scores were 36 (interquartile range 0-43) in the group assigned to IVIG and 31 (0-47) in the group assigned to placebo (mean adjusted difference 1 (95% confidence interval -7 to 10), p = 0.81). The result was supported by analyses adjusted for baseline prognostics, those in the per protocol populations, in the subgroups (site of NSTI) and those done post hoc adjusted for IVIG use before randomisation. Conclusions In ICU patients with NSTI, we observed no apparen…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
The third international consensus definitions for sepsis and septic shock (Sepsis-3).
Singer, M., Deutschman, C. S., Seymour, C. W., Shankar-Hari, M., Annane, D., Bauer, M., Bellomo, R., Bernard, G. R., Chiche, J.-D., Coopersmith, C. M., et al. (2016) · JAMA · doi:10.1001/jama.2016.0287 · Cited by 28,250
Intravenous Fluids and Acute Kidney Injury
Ding, X., Cheng, Z., & Qian, Q. (2017) · Blood Purification · doi:10.1159/000452702 · Cited by 6,827
Diagnosis, evaluation, and management of acute kidney injury: a KDIGO summary (Part 1)
Kellum, J. A., Lameire, N., & for the KDIGO AKI Guideline Work Group (2013) · Critical Care · doi:10.1186/cc11454 · Cited by 2,827
Hydrocortisone Therapy for Patients with Septic Shock
Sprung, C. L., Annane, D., Keh, D., Moreno, R., Singer, M., Freivogel, K., Weiss, Y. G., Benbenishty, J., Kalenka, A., Forst, H., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa071366 · Cited by 2,132
Hydroxyethyl Starch 130/0.42 versus Ringer's Acetate in Severe Sepsis
Perner, A., Haase, N., Guttormsen, A. B., Tenhunen, J., Klemenzson, G., Åneman, A., Madsen, K. R., Møller, M. H., Elkjær, J. M., Poulsen, L. M., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1204242 · Cited by 1,813
Self-citationContrast Medium-Induced Acute Kidney Injury
Sadat, U., Usman, A., Boyle, J. R., Hayes, P. D., & Solomon, R. J. (2015) · Cardiorenal Medicine · doi:10.1159/000430770 · Cited by 1,285
User’s manual for the SF-12v2 health survey
Ware, J., Kosinski, M., Bowker, D., Gandek, B., Ware, J. E., & Turner‐Bowker, D. M. (2002) · Cited by 1,284
The Missing Voice of Patients in Drug-Safety Reporting
Basch, E. (2010) · New England Journal of Medicine · doi:10.1056/nejmp0911494 · Cited by 646
Darenberg, J., Ihendyane, N., Sjolin, J., Aufwerber, E., Haidl, S., Follin, P., Andersson, J., Norrby-Teglund, A., & The Streptlg Study Group (2003) · Clinical Infectious Diseases · doi:10.1086/376630 · Cited by 573
Self-citationKaul, R., McGeer, A., Norrby‐Teglund, A., Kotb, M., Schwartz, B., O'Rourke, K., Talbot, J., Low, D. E., & The Canadian Streptococcal Study Group (1999) · Clinical Infectious Diseases · doi:10.1086/515199 · Cited by 544
Self-citation
Cited by
Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021
Evans, L., Rhodes, A., Alhazzani, W., Antonelli, M., Coopersmith, C. M., French, C., Machado, F. R., Mcintyre, L., Ostermann, M., Prescott, H. C., et al. (2021) · Intensive Care Medicine · doi:10.1007/s00134-021-06506-y · Cited by 5,082
Self-citationSurviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021.
Evans, L., Rhodes, A., Alhazzani, W., Antonelli, M., Coopersmith, C. M., French, C., Machado, F. R., Mcintyre, L., Ostermann, M., Prescott, H. C., et al. (2021) · Critical Care Medicine · doi:10.1097/ccm.0000000000005337 · Cited by 2,935
Self-citationEvaluation and Management of Necrotizing Soft Tissue Infections
Bonne, S. L., & Kadri, S. S. (2017) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2017.05.011 · Cited by 267
“In 2017, the Immunoglobulin G for Patients with Necrotizing Soft Tissue Infection (INSTINCT) study, a Danish multicenter randomized controlled trial also evaluating the adjunctive potential of 3 days of IVIG therapy in NSTI found no benefit of the same on physical functioning or survival at 6-months.(58) Plasmapheresi…”
Egi, M., Ogura, H., Yatabe, T., Atagi, K., Inoue, S., Iba, T., Kakihana, Y., Kawasaki, T., Kushimoto, S., Kuroda, Y., et al. (2021) · Journal of Intensive Care · doi:10.1186/s40560-021-00555-7 · Cited by 224
Necrotizing skin and soft-tissue infections in the intensive care unit
Peetermans, M., de Prost, N., Eckmann, C., Norrby-Teglund, A., Skrede, S., & De Waele, J. J. (2020) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2019.06.031 · Cited by 185
“The INSTINCT randomized trial of IVIG in NSTI of all 347 etiologies observed no apparent effect of IVIG on self-reported physical functioning and mortality 348 [109].”
MethodSelf-citationNecrotising soft-tissue infections
Hua, C., Urbina, T., Bosc, R., Parks, T., Sriskandan, S., de Prost, N., & Chosidow, O. (2023) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(22)00583-7 · Cited by 165
INFECT study group, Madsen, M. B., Skrede, S., Perner, A., Arnell, P., Nekludov, M., Bruun, T., Karlsson, Y., Hansen, M. B., Polzik, P., et al. (2019) · Intensive Care Medicine · doi:10.1007/s00134-019-05730-x · Cited by 173
Self-citationBruun, T., Rath, E., Madsen, M. B., Oppegaard, O., Nekludov, M., Arnell, P., Karlsson, Y., Babbar, A., Bergey, F., Itzek, A., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa027 · Cited by 134
“Some of the patients in our study were coenrolled in a recent randomized trial of IVIG in NSTI of all microbiological etiologies; in which no effect of IVIG was found on physical quality of life [38].”
Self-citationStreptococcal toxic shock syndrome in the intensive care unit
Schmitz, M., Roux, X., Huttner, B. D., & Pugin, J. (2018) · Annals of Intensive Care · doi:10.1186/s13613-018-0438-y · Cited by 121
Necrotizing Soft Tissue Infections
Stevens, D. L., Bryant, A. E., & Goldstein, E. J. (2021) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2020.10.004 · Cited by 113
Advances in Immune Monitoring Approaches for Sepsis-Induced Immunosuppression
Yao, R.-Q., Ren, C., Zheng, L., Xia, Z., & Yao, Y.-M. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.891024 · Cited by 106
Necrotizing Soft Tissue Infections
McDermott, J., Kao, L. S., Keeley, J. A., Grigorian, A., Neville, A. L., & de Virgilio, C. (2024) · JAMA Surgery · doi:10.1001/jamasurg.2024.3365 · Cited by 93
Duane, T. M., Huston, J. M., Collom, M., Beyer, A., Parli, S. E., Buckman, S. A., Shapiro, M. A., McDonald, A. A., Diaz, J. J., Tessier, J. M., et al. (2021) · Surgical Infections · doi:10.1089/sur.2020.436 · Cited by 106
“[167] performed a randomized, blinded, placebo-controlled trial (Immunoglobulin G for patients with necrotizing soft tissue infection [INSTINCT]) on 100 ICU patients with NSTI to evaluate the effect of once-daily IVIG on self-reported physical activity and function six months after treatment.”
Egi, M., Ogura, H., Yatabe, T., Atagi, K., Inoue, S., Iba, T., Kakihana, Y., Kawasaki, T., Kushimoto, S., Kuroda, Y., et al. (2021) · Acute Medicine & Surgery · doi:10.1002/ams2.659 · Cited by 96
Fournier Gangrene: A Review for Emergency Clinicians
Montrief, T., Long, B., Koyfman, A., & Auerbach, J. S. (2019) · Journal of Emergency Medicine · doi:10.1016/j.jemermed.2019.06.023 · Cited by 94
Expert consensus on the monitoring and treatment of sepsis-induced immunosuppression
Pei, F., Yao, R.-Q., Ren, C., Bahrami, S., Billiar, T. R., Chaudry, I. H., Chen, D., Chen, X., Cui, N., Fang, X., et al. (2022) · Military Medical Research · doi:10.1186/s40779-022-00430-y · Cited by 98
Interventions for necrotizing soft tissue infections in adults
Hua, C., Bosc, R., Sbidian, É., de Prost, N., Hughes, C., Jabre, P., Chosidow, O., & Cleach, L. L. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011680.pub2 · Cited by 70
Johnson, A. F., & LaRock, C. N. (2021) · Frontiers in Microbiology · doi:10.3389/fmicb.2021.760255 · Cited by 79
Toxic Shock Syndrome: A Literature Review
Atchade, E., de Tymowski, C., Grall, N., Tanaka, S., & Montravers, P. (2024) · Antibiotics · doi:10.3390/antibiotics13010096 · Cited by 66
“Another randomized placebo-controlled study evaluated the effect of IVIG in NSTI and did not demonstrate any effect on mortality [77].”
BackgroundMortality Risk in Necrotizing Fasciitis: National Prevalence, Trend, and Burden
Al‐Qurayshi, Z., Nichols, R. L., Killackey, M. T., & Kandil, E. H. (2020) · Surgical Infections · doi:10.1089/sur.2019.277 · Cited by 60
“still theoretical, partially supported by its efficacy in other type of infection [20].”
BackgroundTreatment of severe skin and soft tissue infections: a review
Burnham, J. P., & Kollef, M. H. (2017) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0000000000000431 · Cited by 67
Impaired B-Cell Maturation Contributes to Reduced B Cell Numbers and Poor Prognosis in Sepsis
Duan, S., Jiao, Y., Wang, J., Tang, D., Xu, S., Wang, R., Jiang, T., Shao, J., He, Z., & Yu, W. (2019) · Shock · doi:10.1097/shk.0000000000001478 · Cited by 59
Shumba, P., Shambat, S. M., & Siemens, N. (2019) · Toxins · doi:10.3390/toxins11060332 · Cited by 62
“In line with this, a recent placebo-controlled clinical trial called INSTINCT, showed no benefit of the IVIG use in NSTIs [255].”
ResultMadsen, M. B., Skrede, S., Bruun, T., Arnell, P., Rosén, A., Nekludov, M., Karlsson, Y., Bergey, F., Saccenti, E., dos Santos, V. A. P. M., et al. (2017) · Acta Anaesthesiologica Scandinavica · doi:10.1111/aas.13024 · Cited by 44
“Necrotizing soft tissue infections (NSTIs) are rare, but devastating diseases with high mortality rates, multiorgan impairment, amputation and impaired quality of life among survivors.(1,2) NSTIs may affect any layer of the soft tissue and typically have a rapid progression.”
BackgroundSelf-citationHarris, K., Proctor, L., Shinar, S., Philippopoulos, E., Yudin, M. H., & Murphy, K. E. (2023) · Acta Obstetricia Et Gynecologica Scandinavica · doi:10.1111/aogs.14500 · Cited by 42
The Japanese Clinical Practice Guidelines for Management of Sepsis and Septic Shock 2024
Shime, N., Nakada, T.-A., Yatabe, T., Yamakawa, K., Aoki, Y., Inoue, S., Iba, T., Ogura, H., Kawai, Y., Kawaguchi, A., et al. (2025) · Journal of Intensive Care · doi:10.1186/s40560-025-00776-0 · Cited by 52
Cellulitis and Soft Tissue Infections
Bystritsky, R. J., & Chambers, H. F. “. (2018) · Annals of Internal Medicine · doi:10.7326/aitc201802060 · Cited by 46
Thänert, R., Itzek, A., Hoßmann, J., Hamisch, D., Madsen, M. B., Hyldegaard, O., Skrede, S., Bruun, T., Norrby‐Teglund, A., INFECT study group, et al. (2019) · Nature Communications · doi:10.1038/s41467-019-11722-8 · Cited by 44
Self-citationPrognostic factors for streptococcal toxic shock syndrome: systematic review and meta-analysis
Bartoszko, J. J., Elias, Z. F., Rudziak, P., Lo, C. K. L., Thabane, L., Mertz, D., & Loeb, M. B. (2022) · BMJ Open · doi:10.1136/bmjopen-2022-063023 · Cited by 43
“7 12 Furthermore, a thorough and systematic review to corroborate this evidence is lacking.”
BackgroundКirov, М. Y., Владимирович, К. В., Николаевич, П. Д., Щеголев, А. В., Babaev, M. A., Belotserkovskiy, B. Z., Bykov, A. O., Gritsan, A. I., Кулабухов, В. В., Kulikov, A. V., et al. (2023) · Annals of critical care · doi:10.21320/1818-474x-2023-4-7-42 · Cited by 44
Thrane, J. F., & Ovesen, T. (2019) · Scandinavian Journal of Infectious Diseases · doi:10.1080/23744235.2019.1597983 · Cited by 37
Bergsten, H., Madsen, M. B., Bergey, F., Hyldegaard, O., Skrede, S., Arnell, P., Oppegaard, O., Itzek, A., Perner, A., Svensson, M., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa022 · Cited by 33
“In this follow up-study of the INSTINCT trial [1], we show that, in most cases, 25 g IVIG was sufficient to achieve plasma neutralization of GAS superantigenic activity.”
BackgroundResultSelf-citationLaho, D., Blumental, S., Botteaux, A., & Smeesters, P. R. (2021) · Frontiers in Pediatrics · doi:10.3389/fped.2021.697938 · Cited by 33
Aggressive Soft Tissue Infections
Garcia, N. M., & Cai, J. (2018) · Surgical Clinics of North America · doi:10.1016/j.suc.2018.05.001 · Cited by 34
The intricate pathogenicity of Group A Streptococcus : A comprehensive update
Bergsten, H., & Nizet, V. (2024) · Virulence · doi:10.1080/21505594.2024.2412745 · Cited by 35
“A single-center randomized controlled study of adjunctive IVIG in NSTI of all microbiological etiologies showed no benefit [250].”
BackgroundIntravenous immunoglobulin for adjunctive treatment of severe infections in ICUs
Aubron, C., Berteau, F., & Sparrow, R. L. (2019) · Current Opinion in Critical Care · doi:10.1097/mcc.0000000000000639 · Cited by 27
Understanding necrotizing soft tissue infections in the intensive care unit
Urbina, T., Madsen, M. B., & de Prost, N. (2020) · Intensive Care Medicine · doi:10.1007/s00134-020-06071-w · Cited by 24
“There is a theoretical rationale for intravenous immunoglobulins in GAS infections, but the only randomized trial focusing on NSTIs could not find a benefit [14].”
BackgroundSelf-citationTarnutzer, A., Andreoni, F., Keller, N., Zürcher, C., Norrby‐Teglund, A., Schüpbach, R. A., & Zinkernagel, A. S. (2018) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2018.07.007 · Cited by 21
Self-citationSenda, A., Endo, A., Fushimi, K., & Otomo, Y. (2023) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2023.08.011 · Cited by 20
Hofmaenner, D. A., Wendel‐Garcia, P. D., Blum, M. R., David, S., Schuepbach, R. A., Buehler, P. K., Frey, P. M., Zinkernagel, A. S., & Brugger, S. D. (2022) · BMC Infectious Diseases · doi:10.1186/s12879-022-07135-6 · Cited by 19
“In a randomised study including patients with NSTI and SAPS II scores similar to our patients, no effect of IVIG was found on the incidence of acute kidney injury, mechanical ventilation or decline of the Sequential Organ Failure Assessment (SOFA) score [22].”
ResultBahnan, W., Happonen, L., Khakzad, H., Ahnlide, V. K., de Neergaard, T., Wrighton, S., André, O., Bratanis, E., Tang, D., Hellmark, T., et al. (2022) · EMBO Molecular Medicine · doi:10.15252/emmm.202216208 · Cited by 25
“In severe life-threatening invasive GAS infections, intravenous IgG antibodies (IVIG) from human pooled plasma have been used as therapy, even though reports on their efficacy show contradictory results (Linn (cid:1) er et al , 2014; Kadri et al , 2017; Madsen et al , 2017; Parks et al , 2018).”
ResultICU Management of Invasive β-Hemolytic Streptococcal Infections
Babiker, A. Y. M., & Kadri, S. S. (2022) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2022.07.007 · Cited by 19
The Japanese Clinical Practice Guidelines for Management of Sepsis and Septic Shock 2024
Shime, N., Nakada, T., Yatabe, T., Yamakawa, K., Aoki, Y., Inoue, S., Iba, T., Ogura, H., Kawai, Y., Kawaguchi, A., et al. (2025) · Acute Medicine & Surgery · doi:10.1002/ams2.70037 · Cited by 27
Periorbital necrotizing fasciitis
Wladis, E. J. (2022) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2022.02.006 · Cited by 17
Essentials in the management of necrotizing soft-tissue infections
Jung, N., & Eckmann, C. (2019) · Infection · doi:10.1007/s15010-019-01316-3 · Cited by 17
Toxic Shock Syndrome after Surgery: Case Presentation and Systematic Review of the Literature
Celie, K., Colen, D. L., & Kovach, S. J. (2020) · Plastic & Reconstructive Surgery Global Open · doi:10.1097/gox.0000000000002499 · Cited by 16
Clinical practice of sepsis-induced immunosuppression: Current immunotherapy and future options
Pei, F., Gu, B., Miao, S., Guan, X., & Wu, J. (2023) · Chinese Journal of Traumatology · doi:10.1016/j.cjtee.2023.11.001 · Cited by 21
Babbar, A., Bruun, T., Hyldegaard, O., Nekludov, M., Arnell, P., INFECT Study Group, Pieper, D. H., & Itzek, A. (2018) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiy110 · Cited by 13
Self-citationCurrent management of necrotizing soft-tissue infections
Eckmann, C., & Montravers, P. (2020) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0000000000000700 · Cited by 14
“In a randomized clinical trial, the administration of polyspecific IVIG in patients with NSTI was not associated with positive clinical effects in terms of increased survival rates or increased physical functioning score values self-reported by the affected patients [41].”
BackgroundSartelli, M., Coccolini, F., Labricciosa, F. M., Al‐Hasan, M. N., Buonomo, L. A., Cheadle, W. G., de Simone, B. D., Duane, T. M., Hardcastle, T. C., Hecker, A., et al. (2025) · The Journal of Trauma: Injury, Infection, and Critical Care · doi:10.1097/ta.0000000000004833 · Cited by 14
Bassetti, M., Giacobbe, D. R., Larosa, B., Lamarina, A., Vena, A., & Brucci, G. (2025) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0000000000001095 · Cited by 13
Ruiz‐Rodríguez, J. C., Chiscano‐Camón, L., Maldonado, C., Ruiz‐Sanmartín, A., Martin, L., Bajaña, I., Bastidas, J., López‐Martínez, R., Franco‐Jarava, C., González‐López, J. J., et al. (2024) · Antibiotics · doi:10.3390/antibiotics13020187 · Cited by 14
“In line with guidelines from the Infectious Diseases Society of America (IDSA), there is an emphasis on the necessity for further studies to assess the efficacy of IVIG for this particular indication [48].”
Girardis, M., Coloretti, I., Antonelli, M. M., Berlot, G., Busani, S., Cortegiani, A., PASCALE, G. D., Rosa, F. G. D., Rosa, S. D., Donadello, K., et al. (2024) · Journal of Anesthesia Analgesia and Critical Care · doi:10.1186/s44158-024-00165-3 · Cited by 20
Urbina, T., Hua, C., Woerther, P., Dessap, A. M., Chosidow, O., & de Prost, N. (2019) · Critical Care · doi:10.1186/s13054-019-2708-y · Cited by 10
Multidisciplinary management in Fournier's gangrene
Koch, G. E., Abbasi, B., Agoubi, L. L., Breyer, B. N., Clark, N. M., Dick, B. P., Friedrich, J. B., Hampson, L. A., Hernandez, A. H., Maine, R. G., et al. (2024) · Current Problems in Surgery · doi:10.1016/j.cpsurg.2024.101499 · Cited by 17
Charlier, C., Souhail, B., Dauger, S., Woerther, P., Bleibtreu, A., Caséris, M., Chosidow, O., Bertolus, C., Hua, C., Monsel, G., et al. (2025) · Critical Care · doi:10.1186/s13054-025-05664-5 · Cited by 11
“A recent randomized controlled trial by Madsen et al. found no significant benefit of IVIGs on physical quality of life, mortality, or complications at 180 days [77].”
Leeies, M., Gershengorn, H. B., Charbonney, E., Kumar, A., Fergusson, D. A., Turgeon, A. F., Cowan, J., Paunovic, B. N., Embil, J. M., Garland, A., et al. (2021) · Canadian Journal of Anesthesia/Journal canadien d anesthésie · doi:10.1007/s12630-021-01941-3 · Cited by 9
Yoshizawa, S., Matsumura, T., Ikebe, T., Ichibayashi, R., Fukui, Y., Satoh, T., Tsubota, T., Honda, M., Ishii, Y., Tateda, K., et al. (2019) · Journal of Infection and Chemotherapy · doi:10.1016/j.jiac.2019.01.006 · Cited by 9
Fungal Necrotizing Skin and Soft Tissue Infections
Bartram, L., & Aaron, J. G. (2019) · Current Fungal Infection Reports · doi:10.1007/s12281-019-00355-5 · Cited by 8
Therapeutic targets in necrotizing soft tissue infections
de Prost, N., Lipman, J., & Mimoz, O. (2017) · Intensive Care Medicine · doi:10.1007/s00134-017-4813-1 · Cited by 9
“have performed the INSTINCT trial [16]—a blinded randomized placebocontrolled study recently published in Intensive Care Medicine—in which they evaluated the effect of IVIG on patient-reported quality of life, as assessed by the physical *Correspondence: nicolas.”
BackgroundMethodSurgical site infections after cesarean delivery
Hayasaka, M., Landy, H. J., Forbes, L. A., Barger, A., Gangji, S. N., Saade, G. R., & Kawakita, T. (2026) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2025.08.008 · Cited by 11
Portefaix, A., Dhelens, C., Recher, M., Cour‐Andlauer, F., Naudin, J., Mortamet, G., Joram, N., Tissières, P., Ginhoux, T., Kassaï, B., et al. (2024) · Archives of Disease in Childhood · doi:10.1136/archdischild-2022-325274 · Cited by 8
Severe Skin and Soft-Tissue Infections
Stieferman, A. E., Mazi, P. B., & Burnham, J. P. (2022) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0041-1740974 · Cited by 8
Nekrotisierende Fasziitis der Kopf-Hals-Region – 3 Fallberichte und Literaturübersicht
Huber, L., Budjan, J., Rotter, N., & Lammert, A. (2020) · HNO · doi:10.1007/s00106-020-00899-w · Cited by 8
Hansen, S. U.-B., Jespersen, F. V. B., Markvart, M., Hyldegaard, O., Plaschke, C. C., Bjarnsholt, T., Nielsen, C. H., & Jensen, S. S. (2023) · Acta Odontologica Scandinavica · doi:10.1080/00016357.2023.2254389 · Cited by 7
“…of intravenous immunoglobulin g (iVig) (except for patients participating in the iNstiNct study who were randomized to iVig or placebo) [13] and hyper-baric oxygen (hBO) treatment. exclusion criteria were patients ≤18 years of age and missing medical records or radiographic material…”
BackgroundSelf-citationTreatment of Necrotizing Soft Tissue Infections: IVIG
Madsen, M. B., Bergsten, H., & Norrby‐Teglund, A. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-57616-5_8 · Cited by 7
Self-citationNecrotising soft tissue infections
Gundersen, I. M., Bruun, T., Almeland, S. K., Skutlaberg, D. H., Nedrebø, T., Rath, E., Oppegaard, O., Guttormsen, A. B., Norrby‐Teglund, A., Mosevoll, K. A., et al. (2024) · Tidsskrift for Den norske legeforening · doi:10.4045/tidsskr.23.0720 · Cited by 7
Self-citationNekrotisierende Fasziitis der Extremitäten und des Stamms
Eckmann, C., & Maier, S. (2019) · Der Chirurg · doi:10.1007/s00104-019-01082-w · Cited by 9
Bahnan, W., Happonen, L., Khakzad, H., Ahnlide, V. K., de Neergaard, T., Wrighton, S., André, O., Bratanis, E., Tang, D., Hellmark, T., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.03.01.433494 · Cited by 7
de Haan, J., Neeter, L. M. F. H., Suijker, J., van Zuijlen, P. P. M., Pijpe, A., Vries, A. M., NSTI Knowledge Collaborative Group, Bonjer, H. J., Nieuwenhuis, M. K., van der Vlies, C. H., et al. (2025) · European Journal of Trauma and Emergency Surgery · doi:10.1007/s00068-025-03000-8 · Cited by 5
“However, robust scientific evidence for these treatments remains limited, and in the current cohort, the mortality rate of septic patients who received IVIG treatment was comparable to those who did not [17, 18].”
Neff, A., Chok, L., von Both, U., Matt, U., Tarnutzer, A., Andreoni, F., van der Linden, M., Plock, J. A., Buehler, P. K., Brugger, S. D., et al. (2020) · Swiss Medical Weekly · doi:10.4414/smw.2020.20378 · Cited by 4
Focus on randomised clinical trials
Perner, A., Hjortrup, P. B., & Pettilä, V. (2018) · Intensive Care Medicine · doi:10.1007/s00134-018-5468-2 · Cited by 6
Self-citationTreating necrotizing skin and soft-tissue infections
Montravers, P., Norrby‐Teglund, A., & Muñóz, P. (2024) · Intensive Care Medicine · doi:10.1007/s00134-024-07466-9 · Cited by 5
“A placebo-controlled trial of IVIG in NSTI patients did not show any difference in the physical quality of life (primary endpoint) between the IVIG group and the placebo group [14].”
Self-citationComplicated and deep bacterial skin and soft tissue infections
Prodinger, C. M., Lechner, A. M., Hintersteininger, A., Kern, J. M., Meissnitzer, M. W., Meyersburg, D., Bauer, J. W., & Laimer, M. (2025) · JDDG Journal der Deutschen Dermatologischen Gesellschaft · doi:10.1111/ddg.15493 · Cited by 4
He, W., Wu, C., Zhong, Y., Li, J., Wang, G., Yu, B., Xu, P., Xiao, Y., & Tang, T. (2022) · Frontiers in Public Health · doi:10.3389/fpubh.2022.899077 · Cited by 5
Pravia, O. V. B., Díaz-Cámara, M., La, O. D., Pey, C., Martín, M. O., Hiscock, L. J., Bellido, B. M., & Sánchez, Á. L. C. (2017) · Medicine · doi:10.1097/md.0000000000008708 · Cited by 4
Intravenous immunoglobulin in sepsis: can we find the right dose?
Szakmány, T. (2019) · Minerva Anestesiologica · doi:10.23736/s0375-9393.18.13349-9 · Cited by 4
Leeies, M., Gershengorn, H. B., Charbonney, E., Kumar, A., Fergusson, D. A., Turgeon, A. F., Cowan, J., Paunovic, B. N., Embil, J. M., Houston, D. S., et al. (2021) · Canadian Journal of Anesthesia/Journal canadien d anesthésie · doi:10.1007/s12630-021-01964-w · Cited by 4
Skin and soft tissue infections. Draft of clinical guidelines
Mitish, V. A., Paskhalova, Y. S., Tsvetkov, V. O., Borisov, I. V., Kolovanova, O. V., Osmanov, E. G., & Anishchenko, M. A. (2025) · Wounds and wound infections The prof B M Kostyuchenok journal · doi:10.25199/2408-9613-2025-12-1-6-57 · Cited by 5
Current status of immunomodulatory therapies in adult sepsis patients: where do we stand?
Papatheodosiou, D., Giamarellos‐Bourboulis, E. J., & Tsoukas, C. (2026) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2026.2646192 · Cited by 3
“The primary endpoint was the patient's perceived physical status, appraised at a 6-month timepoint [110].”
Windsor, C., Urbina, T., & de Prost, N. (2023) · Current Opinion in Critical Care · doi:10.1097/mcc.0000000000001069 · Cited by 3
“[56] recently conducted a randomized, blinded, placebo-controlled trial including only NSTI patients and observed no statistically significant differences in physical quality of life at 180days between patients allocated to three doses of IVIG and the placebo group.”
MethodNecrotizing Fasciitis of the Upper Extremity: A Systematic Review of the Literature
Bilolikar, V. K., Rengifo, S., Desai, K., & Hozack, B. A. (2023) · SurgiColl · doi:10.58616/001c.84186 · Cited by 3
Nekrotisierende Weichteilinfektionen
Dünser, M. W., Eichler, B., & Salzer, H. J. F. (2024) · Anästhesie Nachrichten · doi:10.1007/s44179-024-00217-7 · Cited by 3
Urbina, T., Madsen, M. B., Hua, C., Eckmann, C., Elhadi, M., Gurjar, M., PASCALE, G. D., Zand, F., Hästbacka, J., Ferrer, R., et al. (2025) · Infectious Diseases Now · doi:10.1016/j.idnow.2025.105033 · Cited by 2
Self-citationWrighton, S., & Nordenfelt, P. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1771053 · Cited by 3
Urbina, T., Hua, C., Sbidian, É., Oro, S., Duong, T. A., Wolkenstein, P., Bosc, R., Razazi, K., Carteaux, G., Chosidow, O., et al. (2018) · Médecine Intensive Réanimation · doi:10.3166/rea-2018-0064 · Cited by 2
Menon, B., Krishna, M., Galagali, A., & Mehrotra, S. (2020) · Indian Journal of Surgery · doi:10.1007/s12262-020-02268-x · Cited by 2
“A randomized control study INSTINCT compared the effect of placebo vs IVIG on self-reported physical function in ICU patients [16].”
MethodHedetoft, M., Madsen, M. B., Perner, A., Garred, P., & Hyldegaard, O. (2021) · Acta Anaesthesiologica Scandinavica · doi:10.1111/aas.13942 · Cited by 2
Self-citationTop unanswered questions in antimicrobial management of necrotizing soft tissue infections
Mitaka, H., Chan, J. D., Bisgaard, E., Lynch, J. B., & Bryson‐Cahn, C. (2025) · Antimicrobial Stewardship & Healthcare Epidemiology · doi:10.1017/ash.2025.10268 · Cited by 1
“46 Similarly, a recent cohort study of clindamycin-treated NSTI patients reported no difference in ICU length of stay or mortality between patients with or without IVIG.”
van Kempen, E. B., Malmgren, A., Elfving, K., Cohen, J. F., & Borensztajn, D. (2026) · European Journal of Pediatrics · doi:10.1007/s00431-026-06797-7 · Cited by 1
“A randomized controlled trial (RCT) published in 2018 on 100 adults with NF showed no difference in 30-day mortality nor serious adverse events between IVIG and placebo groups [20].”
„Tempus fugit, venit mors” – a streptococcalis toxikus sokk szindrómáról egy eset kapcsán
Szabó, B. G., Kiss, R., Lénárt, K. S., Nikolova, R., & Kádár, B. (2019) · Orvosi Hetilap · doi:10.1556/650.2019.31597 · Cited by 1
Necrotizing Soft Tissue Infections: Case Reports, from the Clinician’s Perspectives
Nedrebø, T., & Skrede, S. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-57616-5_3 · Cited by 1
From the Cochrane Library: Interventions for Necrotizing Soft Tissue Infections in Adults
Shakshouk, H., Hua, C., Adler, B. L., & Ortega‐Loayza, A. G. (2021) · JMIR Dermatology · doi:10.2196/34578 · Cited by 1
“IVIGc vs placebo, Madsen et al [5] AB103 vs placebo, Bulger et al [4] MXFa vs AM-CLb, Vick-Fragoso et al [3]”
BackgroundBrehm, T. T., Matthews, H., & Hennigs, A. (2024) · Die Innere Medizin · doi:10.1007/s00108-024-01662-x · Cited by 1
Komplizierte und tiefe bakterielle Haut‐ und Weichteilinfektionen
Prodinger, C. M., Lechner, A. M., Hintersteininger, A., Kern, J. M., Meissnitzer, M. W., Meyersburg, D., Bauer, J. W., & Laimer, M. (2025) · JDDG Journal der Deutschen Dermatologischen Gesellschaft · doi:10.1111/ddg.15493_g · Cited by 1
Common Infections in the Intensive Care Unit
Mahmoud, A. A., Halawi, H., Sabawi, M. M., & Adelman, M. W. (2025) · Springer eBooks · doi:10.1007/978-3-031-77335-8_29 · Cited by 2
Management of Necrotizing Fasciitis
Abdel‐Kader, S., Sartelli, M., & Abu‐Zidan, F. M. (2021) · Hot topics in acute care surgery and trauma · doi:10.1007/978-3-030-62116-2_14 · Cited by 1
Management of Necrotizing Soft Tissue Infection
Evans, H. L., Napolitano, L. M., & Bulger, E. M. (2020) · Springer eBooks · doi:10.1007/978-3-030-26710-0_93 · Cited by 1
Management of Necrotizing Soft Tissue Infection
Evans, H. L., & Bulger, E. M. (2017) · Springer eBooks · doi:10.1007/978-3-319-43341-7_85
IVIG of Unproven Benefit for Necrotizing Soft Tissue Infections
Glück, T. (2017) · Journal watch · doi:10.1056/nejm-jw.na44263
Metadata
- Authors
- Madsen, M. B., Hjortrup, P. B., Hansen, M. B., Lange, T., Norrby-Teglund, A., Hyldegaard, O., & Perner, A.
- Affiliations
- Copenhagen University Hospital (DK)
- University of Copenhagen (DK)
- Corresponding author
- Perner, Anders
- Venue
- Intensive Care Medicine
- Published
- 2017-04-18
- Volume
- 43
- Issue
- 11
- Pages
- 1585-1593
- ISSN
- 0342-4642 (ISSN-L)
- 1432-1238
- OpenAlex
- W2607400732
- Semantic Scholar
- 166c099a9f14ad8bfdf6ca402f44b57fdc54130b
- Cited by
- 128
- References
- 39
- Citations by year
- 2026: 13 · 2025: 20 · 2024: 12 · 2023: 9 · 2022: 12 · 2021: 14 · 2020: 17 · 2019: 15 · 2018: 9 · 2017: 7
- FWCI
- 12.33
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Intensive Care Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Funders
- CSL Behring
- EU 7th Framework program
- Topics
- Health Sciences › Medicine › Infectious Diseases › Streptococcal Infections and Treatments
- Health Sciences › Medicine › Critical Care and Intensive Care Medicine › Sepsis Diagnosis and Treatment
- Health Sciences › Medicine › Infectious Diseases › Otolaryngology and Infectious Diseases
- Keywords
- necrotizing soft tissue infection, intravenous immunoglobulin G, physical function, intensive care unit patients, SF-36 physical component summary, adjuvant therapy, acute kidney injury, wound infection
- MeSH terms
- Aged, Critical Care, Double-Blind Method, Female, Humans, Immunologic Factors, Infusions, Intravenous, Intensive Care Units, Male, Middle Aged, Necrosis, Quality of Life, Immunoglobulins, Intravenous, Treatment Outcome, Soft Tissue Infections, Intention to Treat Analysis, Self Report, Acute Kidney Injury
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.